pH-Responsive Artemisinin Derivatives and Lipid Nanoparticle Formulations Inhibit Growth of Breast Cancer Cells In Vitro and Induce Down-Regulation of HER Family Members
Open Access
- 14 March 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (3), e59086
- https://doi.org/10.1371/journal.pone.0059086
Abstract
Artemisinin (ART) dimers show potent anti-proliferative activities against breast cancer cells. To facilitate their clinical development, novel pH-responsive artemisinin dimers were synthesized for liposomal nanoparticle formulations. A new ART dimer was designed to become increasingly water-soluble as pH declines. The new artemisinin dimer piperazine derivatives (ADPs) remained tightly associated with liposomal nanoparticles (NPs) at neutral pH but were efficiently released at acidic pH's that are known to exist within solid tumors and organelles such as endosomes and lysosomes. ADPs incorporated into nanoparticles down regulated the anti-apoptotic protein, survivin, and cyclin D1 when incubated at low concentrations with breast cancer cell lines. We demonstrate for the first time, for any ART derivative, that ADP NPs can down regulate the oncogenic protein HER2, and its counterpart, HER3 in a HER2+ cell line. We also show that the wild type epidermal growth factor receptor (EGFR or HER1) declines in a triple negative breast cancer (TNBC) cell line in response to ADP NPs. The declines in these proteins are achieved at concentrations of NP109 at or below 1 µM. Furthermore, the new artemisinin derivatives showed improved cell-proliferation inhibition effects compared to known dimer derivatives.This publication has 64 references indexed in Scilit:
- Artemisinin: Discovery from the Chinese Herbal GardenCell, 2011
- Endosome maturationThe EMBO Journal, 2011
- Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinaseProceedings of the National Academy of Sciences of the United States of America, 2011
- The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeuticsSeminars in Cell & Developmental Biology, 2010
- Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trialThe Lancet, 2010
- Characteristics of triple-negative breast cancerZeitschrift für Krebsforschung und Klinische Onkologie, 2010
- Effect of artemisinin derivatives on apoptosis and cell cycle in prostate cancer cellsAnti-Cancer Drugs, 2010
- Suppression of Cancer Cell Growth by Promoting Cyclin D1 DegradationMolecular Cell, 2009
- Artemisinin dimer anticancer activity correlates with heme‐catalyzed reactive oxygen species generation and endoplasmic reticulum stress inductionInternational Journal of Cancer, 2009
- Reflections on the ‘discovery’ of the antimalarial qinghaoBritish Journal of Clinical Pharmacology, 2006